ERNEXA THERAPEUTICS INC (ERNA) Stock News

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

New entity, ErnexaTX2, reflects progress toward clinical readiness...

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Conference attendees will get first look at new data that supports the potential of ERNA-101 to boost anti-tumor immunity in ovarian cancer...

12 Health Care Stocks Moving In Thursday's After-Market Session

Mentions: ACET SYRA CLSD SLNO ...

12 Health Care Stocks Moving In Thursday's After-Market Session

Mentions: SGMO IBO ALDX BBLG ...

Ernexa Therapeutics Closes New Funding Round

Comes on the heels of company’s rebranding and new strategic direction, advancing its lead program in ovarian cancer...

Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease

Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development

Eterna Therapeutics Announces Expansion of Scientific Advisory Board

Dr. Jerome Zeldis and Dr. ...

ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eterna Therapeutics (NASDAQ:ERNA) just reported results for the second quarter ...

ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q2 2024

Eterna Therapeutics just reported results for the second quarter of 2024.

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Meeting addressed progress and strategic direction for company’s induced mesenchymal stem cell (iMSC) therapy programs...

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Eterna Therapeutics announced positive results from a preclinical study on the company’s lead cell therapy product, ERNA-101....

ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eterna Therapeutics (NASDAQ:ERNA) just reported results for the first quarter o...

ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q1 2024

Eterna Therapeutics just reported results for the first quarter of 2024.

ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023

Eterna Therapeutics just reported results for the fourth quarter of 2023.

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

World-renowned researcher brings expertise in obstetrics and gynecology from Yale University to advance Eterna’s lead indication in ovarian cancer...

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program

Eterna Therapeutics Announces $1 Million Stock Repurchase Program...

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing ...

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success...

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience Limited...

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

Eterna Therapeutics to Present at ASGCT on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line...

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board...

ISRG Stock Alert: The FDA Is Giving Intuitive Surgical a Big Boost

Intuitive Surgical stock is on the rise Friday as investors in ISRG shares learn about FDA approval for the company's da Vinci 5.

Mentions: ISRG RIVN KOPN

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Eterna Therapeutics (ERNA) Announces the Appointment of Peter Cicala, JD, to its Board of Directors...

Eterna Therapeutics files to sell 18.2M shares for holders (NASDAQ:ERNA)

Eterna Therapeutics files prospectus for $25M mixed shelf offering, not an offer to sell securities.

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed...